Global Mofy AI Limited Announces Effective Date of Reverse Stock Split

Global Mofy AI Limited (Nasdaq: GMM) said its reverse stock split will take effect on June 11, 2026 at a 1-for-50 ratio for its class A and class B ordinary shares. Trading begins on an adjusted basis that date. The company said class A shares fall from ~89.58M to ~1.79M and class B from ~8.17M to ~0.16M; no fractional shares will be issued.

Original reporting
Published Jun 9, 2026, 4:30 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 9, 2026, 5:29 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Global Mofy AI Limited Announces Effective Date of Reverse Stock Split — source image
Decision brief

The 30-second read

$GMMNeutralMed
01

Why it matters

The key tradable element is the effective date and ratio, which can cause mechanical price changes and short-term liquidity/sentiment effects; it does not include new financial performance or guidance.

02

Market read

Actionable for execution/risk management around June 11; potential for short-term volatility but no fundamental catalyst is disclosed.

03

What to watch

Traders should account for order-book/limit-price adjustments, potential changes in bid-ask spreads, and any downstream effects on options/ETFs that reference the share price.

Relevance 6/10Novelty 6/10Timing: Adjusted trading begins June 11, 2026 (reverse split effective).

Background

The company resolved to implement a reverse stock split after shareholders authorized a range (1-for-2 to 1-for-500) and the board set the ratio at 1-for-50.

Company-level read

Ticker impact

$GMMNeutralMedium confidence
Context

Global Mofy AI Limited announced a 1-for-50 reverse stock split effective June 11, 2026, with adjusted trading under the same ticker.

Expected impact

Near-term volatility risk around June 11 due to mechanical price adjustment and potential sentiment/liquidity effects; direction is uncertain.

Evidence & confidence

The article discloses the exact split ratio (1-for-50) and the adjusted trading start date (June 11), which is actionable for execution and risk controls, but it does not provide fundamentals or guidance changes.

Market effects

Limited direct read-across; reverse splits are company-specific corporate actions rather than sector fundamentals.

Primarily impacts Nasdaq-listed microcap/small-cap liquidity and trading mechanics; broader regional effects unlikely.

Low global relevance beyond the issuer’s capital structure and trading behavior.

Counterpoint

Because the ticker remains the same and the split is purely mechanical, long-term holders may see limited economic change aside from per-share quoting and potential sentiment noise.

Key entities

  • Global Mofy AI Limited

    Nasdaq-listed generative AI/3D digital asset company implementing a 1-for-50 reverse stock split.

  • Reverse stock split

    1-for-50 consolidation of class A and class B ordinary shares; adjusted trading begins June 11, 2026.

Related articles

$GMMMedAI 8/10

Global Mofy Reports 49.4% YoY Revenue Increase for the Six Months Ended March 31, 2026, Driven by Virtual Tech Growth and New AI Digital Asset Business

Global Mofy AI Limited (Nasdaq: GMM) reported six-month results ended March 31, 2026. Revenue rose 49.4% to $39.9 million from $26.7 million. R&D increased to $14.4 million. GAAP net loss was $50.7 million, while non-GAAP net income was $1.1 million, with higher costs tied to virtual production and a new digital asset sales business.

$GMMMedAI 8/10

D. Boral Capital Acted as Exclusive Placement Agent to Global Mofy AI Limited in Connection with its ~$8,000,000 Registered Direct Offering

Global Mofy AI Limited (Nasdaq:GMM) closed a registered direct offering on May 26, 2026, selling 8,247,420 Class A ordinary shares plus Series A and Series B warrants to buy up to 8,247,420 shares each. The offering price was $0.97 per share, raising about $8.0 million gross. D. Boral Capital was exclusive placement agent; net proceeds will fund general corporate purposes.

$GMMMed

Global Mofy Enters into Cooperation with Amazon Web Services (AWS) and Advances AIGC Computing Infrastructure Deployment

Global Mofy AI Limited (Nasdaq: GMM) said it entered into cooperation with Amazon Web Services to upgrade its digital asset library, deploy cloud infrastructure, and provide related technical support, according to the company. It also announced parallel arrangements to advance its self-developed AIGC intelligent content platform and agent products, which may affect how its services are hosted and scaled.

$GDMedAI 9/10

General Dynamics wins $249m in US military contracts

General Dynamics (GD) won two U.S. military contracts totaling $248.9M. One is a $149.6M contract for USS Pinckney modernization, with potential value up to $149.9M. The other is a $99.3M task order for MUOS Ground Infrastructure Segment upgrades. Both contracts are sole-source and involve work through 2028, funded by fiscal 2026 budgets.

$LMTHighAI 9/10

Lockheed Martin wins $150 million in defense contracts

Lockheed Martin Corp received three contract modifications worth over $150 million from the U.S. Department of Defense. The largest, $90.2 million, is for the TRIDENT II Life Extension 2 program, with work spread across multiple locations. The other contracts, $40.1 million and $20.3 million, are for the MK 41 Vertical Launching System and HH-60W repairs, respectively. Completion dates range from 2027 to 2030.

$NVSMedAI 8/10

Novartis Pharma AG: Novartis announces Lp(a)HORIZON Phase III topline results for pelacarsen in patients with elevated Lp(a) and established cardiovascular disease (CVD)

Novartis announced that the Phase III Lp(a)HORIZON trial for pelacarsen did not meet its primary endpoint of reducing cardiovascular events. The study, involving 8,323 patients, showed that while pelacarsen lowered Lp(a) levels, it did not reduce cardiovascular risk. Novartis obtained rights to pelacarsen from Ionis Pharmaceuticals. Elevated Lp(a) affects about 20% of people worldwide and has no approved targeted treatment.